Tatiana Hernandez, MD
Family Medicine · Trinity, FLNPI 1366535320
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,285 of the $8,283 with a category attached, or 63.8%. 37 manufacturers reported payments, led by Eli Lilly at 37.4% of the total. Reporting peaked in 2020 at $2,708 and has fallen 85.5% since, to $392 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- AstraZeneca$739
- Ferring Pharmaceuticals AS$515
- Lilly USA, LLC$514
- Astellas Pharma US Inc$461
- AbbVie$322
- plus $3K from 31 others
Across 220 payments — averaging $8298.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$631K
- Eli Lilly$554K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$305K
- GSK$132K
- Bristol Myers Squibb$82K
- Ferring International Pharmascience Center US$48K
- plus $75K from 5 others
What the payments were for
- Travel & lodging$2,87235%
- Food & beverage$5,28564%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 25 | $3,096 |
| AstraZeneca | 41 | $739 |
| Ferring Pharmaceuticals AS | 9 | $515 |
| Lilly USA, LLC | 25 | $514 |
| Astellas Pharma US Inc | 15 | $461 |
| AbbVie(2 entities) | 23 | $322 |
| Novo Nordisk | 20 | $312 |
| Boehringer Ingelheim | 13 | $289 |
| Amgen | 15 | $248 |
| GSK | 9 | $207 |
| Johnson & Johnson | 12 | $195 |
| Pfizer | 11 | $179 |
| Novartis | 8 | $143 |
| Amarin Pharma, Inc. | 7 | $141 |
| Bayer | 6 | $112 |
| Dexcom, Inc. | 4 | $90 |
| Abbott | 3 | $65 |
| Exact Sciences | 4 | $60 |
| Scynexis, Inc. | 2 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $53 |
| Insmed, Inc. | 2 | $49 |
| Merck | 3 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $44 |
| Esperion Therapeutics, Inc. | 3 | $35 |
| Medtronic | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17 |
| Nevro Corp. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,283 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $93,438 |
| JanuviaSitagliptin Phosphate | 41 | $47,295 |
| MounjaroTirzepatide | 29 | $36,386 |
| JardianceEmpagliflozin | 32 | $33,499 |
| FarxigaDapagliflozin Propanediol | 29 | $29,703 |
| XareltoRivaroxaban | 21 | $29,557 |
| OzempicSemaglutide | 23 | $27,721 |
| ProliaDenosumab | 12 | $20,861 |
| LinzessLinaclotide | 20 | $20,027 |
| EntrestoSacubitril/Valsartan | 11 | $12,034 |
| LantusInsulin Glargine,hum.Rec.Anlog | 37 | $9,868 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 305 | $8,169 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $7,862 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $7,567 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $6,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $93,43888 claims |
| MerckJanuvia | $47 | $47,29541 claims |
| AstraZenecaFarxiga, Symbicort | $739 | $37,27058 claims |
| Lilly USA, LLCMounjaro | $514 | $36,38629 claims |
| Boehringer IngelheimJardiance | $289 | $33,49932 claims |
| Johnson & JohnsonXarelto | $195 | $29,55721 claims |
| Novo NordiskOzempic | $312 | $27,72123 claims |
| AmgenProlia | $248 | $20,86112 claims |
| AbbVieLinzess | $322 | $20,02720 claims |
| NovartisEntresto | $143 | $12,03411 claims |
| Sanofi-aventis U.S. LLCLantus | $28 | $9,86837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Trinity
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.